vistagan liquifilm 0 5 %, augentropfen
allergan ag - levobunololi hydrochloridum - 5 %, augentropfen - levobunololi hydrochloridum 5 mg, antiox.: e 223, conserv.: benzalkonii chloridum, excipiens ad solutionem pro 1 ml. - glaukom - synthetika human
vistagan liquifilm 0,5% unit dose augentropfen
abbvie ag - levobunololum - augentropfen - levobunololi hydrochloridum 5 mg corresp. levobunololum 4.4 mg, poly(alcohol vinylicus), dinatrii edetas, dinatrii phosphas heptahydricus et kalii dihydrogenophosphas corresp. phosphas 1.9 mg, natrii chloridum, acidum hydrochloridum aut natrii hydroxidum ad ph, aqua purificata ad solutionem pro 1 ml. - glaukom - synthetika
vistagan liquifilm 0,5% o.k. augentropfen
allergan pharmaceuticals ireland - regulatory affairs - - levobunololhydrochlorid - augentropfen - levobunololhydrochlorid 5.mg
vistagan liquifilm 0,5% augentropfen
allergan pharmaceuticals ireland - regulatory affairs - - levobunololhydrochlorid - augentropfen - levobunololhydrochlorid 5.mg
vistagan liquifilm 0 5 %, augentropfen
allergan ag - levobunololi hydrochloridum - 5 %, augentropfen - levobunololi hydrochloridum 5 mg, antiox.: e 223, conserv.: benzalkonii chloridum, excipiens ad solutionem pro 1 ml. - glaukom - synthetika human
vistagan liquifilm 0,5% unit dose collyre
abbvie ag - levobunololum - collyre - levobunololi hydrochloridum 5 mg corresp. levobunololum 4.4 mg, poly(alcohol vinylicus), dinatrii edetas, dinatrii phosphas heptahydricus et kalii dihydrogenophosphas corresp. phosphas 1.9 mg, natrii chloridum, acidum hydrochloridum aut natrii hydroxidum ad ph, aqua purificata ad solutionem pro 1 ml. - le glaucome - synthetika
betagan liquifilm 0,5%, oogdruppels, oplossing
allergan pharmaceuticals ireland castlebar road westport, co. mayo (ierland) - levobunololhydrochloride samenstelling overeenkomend met ; levobunolol - oogdruppels, oplossing - benzalkoniumchloride ; dinatriumedetaat 2-water ; dinatriumwaterstoffosfaat 7-water (e 339) ; kaliumdiwaterstoffosfaat 0-water (e 340) ; natriumchloride ; natriumhydroxide (e 524) ; natriummetabisulfiet (e 223) ; polyvinylalcohol (e1203) ; water, gezuiverd ; zoutzuur (e 507), - levobunolol
iopidine apraclonidine 5mg/ml (as hydrochloride) eye drops bottle
clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.
levobunolol/biomedica 0.5% w/v ey.dro.sol
biomedica ae - levobunolol - ΟΦΘΑΛΜΙΚΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ - 0.5% w/v - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
betagan 0,5 pour cent, collyre en solution
allergan france - lévobunolol (chlorhydrate de) 0 - collyre - 0,5 g - pour 100 ml > lévobunolol (chlorhydrate de 0,5 g - anti-glaucomateux. - il est indiqué dans le traitement de certaines maladies de l'œil comportant une hypertension intra-oculaire (glaucome, hypertonie intra-oculaire).